Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of Atigliflozin in T2DM on Metformin
NCT00361738Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of Atigliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Sanofi. Primary endpoint: Mean Plasma Glucose at 4 weeks. Started Jul 2006; status: completed.
02
Drugs
Atigliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00361738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361738.